EPIC hears that resources are tight for external collaborations at BMS
This article was originally published in Scrip
"There's no money in Bristol-Myers Squibb's budget for external collaborations," Dr Lubor Gaal, head of Europe at BMS's strategic transactions group, told delegates at last week's European Partnering and Investment Conference (EPIC) in London, UK. "Our portfolio is very full."
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.